ZIO-101 (S-dimethylarsino-glutathione): Phase I/II trials in advanced/progressive multiple myeloma
James R. Berenson(Oncotherapeutics (United States)), M. A. Hussein(Cleveland Clinic), Brian Schwartz(Cyclacel Pharmaceuticals (United Kingdom)), Sundar Jaganath(Cleveland Clinic), R. Soebel(Cleveland Clinic), Andrew R. Belch, R. P. Gale(Cleveland Clinic), Ralph V. Boccia(Center for Cancer and Blood Disorders), Donna Reece(Princess Margaret Cancer Centre)
Cited by 7
Related Papers
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Assessment of thymic output in adults after haematopoietic stemcell transplantation and prediction of T-cell reconstitution
|The Lancet|2000|579
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
|The Lancet Oncology|2012|550
Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation
|The Hematology Journal|2003|425